Results 61 to 70 of about 1,227,223 (348)

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer [PDF]

Oncotarget, 2018
Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately lead to improved tumor-targeted treatment options, particularly for subsets of breast cancer patients with unmet needs.
David A. Tice, Shannon Breen, Haihong Zhong, Qun Du, Ronald Herbst, Jiping Zha, Molly Reed, Karma Dacosta, Rakesh Dixit, MaryJane Hinrichs, Lee Brown, Maureen Kennedy, Darrin Sabol, Partha S. Chowdhury, Partha S. Chowdhury, Binyam Bezabeh, Zhan Xiao, Rosa A. Carrasco, Sandrina Phipps, John Meekin, Cui Chen, Joanne Ayriss, Joanne Ayriss, Emily E. Bosco, R. James Christie   +24 more
openaire   +3 more sources

Autophagy in cancer and protein conformational disorders

FEBS Letters, EarlyView.
Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley   +1 more source

Novel Pathways of Oxidative and Nitrosative Inactivation of the Human MGMT Protein in Colon Cancer and Glioblastoma Cells: Increased Efficacy of Alkylating Agents In Vitro and In Vivo

Diseases
Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a unique antimutagenic DNA repair protein that plays a crucial role in conferring resistance to various alkylating agents in brain tumor therapy.
Debasish Basak, Agm Mostofa, Hanumantha Rao Madala, Kalkunte S. Srivenugopal   +3 more
doaj   +1 more source

Clinical connectivity map for drug repurposing: using laboratory tests to bridge drugs and diseases [PDF]

arXiv, 2020
Drug repurposing has attracted increasing attention from both the pharmaceutical industry and the research community. Many existing computational drug repurposing methods rely on preclinical data (e.g., chemical structures, drug targets), resulting in translational problems for clinical trials.
arxiv  

Immuno-oncology trends: preclinical models, biomarkers, and clinical development

Journal for ImmunoTherapy of Cancer, 2022
The landscape in immuno-oncology (I-O) has undergone profound changes since its early beginnings up through the rapid advances happening today.
M. Franklin, S. Platero, K. Saini, G. Curigliano, Steven Anderson   +4 more
semanticscholar   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy

Molecules, 2021
Despite the recent advances in the field of chemically synthetized pharmaceutical agents, nature remains the main supplier of bioactive molecules.
C. Dehelean, I. Marcovici, Codruţa Şoica, Marius Mioc, D. Coricovac, S. Iurciuc, O. Crețu, I. Pinzaru   +7 more
semanticscholar   +1 more source

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

Molecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić, Florian Lüke, Steffi Treitschke, Andrea Coluccio, Martin Hoffmann, Giancarlo Feliciello, Adithi Ravikumar Varadarajan, Xin Lu, Kathrin Weidele, Catherine Botteron, Silvia Materna–Reichelt, Felix Keil, Katja Evert, Florian Weber, Thomas Schamberger, Michael Althammer, Jirka Grosse, Dirk Hellwig, Christian Schulz, Stephan Seitz, Peter Ugocsai, Anke Schlenska‐Lange, Roman Mayr, Ulrich Kaiser, Wolfgang Dietmaier, Bernhard Polzer, Jens Warfsmann, Kamran Honarnejad, Tobias Pukrop, Daniel Heudobler, Christoph A. Klein, Christian Werno   +31 more
wiley   +1 more source

Preclinical evaluation of strasseriolides A–D, potent antiplasmodial macrolides isolated from Strasseria geniculata CF-247,251

Malaria Journal, 2021
Background Malaria is a global health problem for which novel therapeutic compounds are needed. To this end, a recently published novel family of antiplasmodial macrolides, strasseriolides A–D, was herein subjected to in vivo efficacy studies and ...
Frederick Annang, Guiomar Pérez-Moreno, Caridad Díaz, Victor González-Menéndez, Nuria de Pedro Montejo, José Pérez del Palacio, Paula Sánchez, Scott Tanghe, Ana Rodriguez, Ignacio Pérez-Victoria, Juan Cantizani, Luis M. Ruiz-Pérez, Olga Genilloud, Fernando Reyes, Francisca Vicente, Dolores González-Pacanowska   +15 more
doaj   +1 more source

Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance

Molecular Oncology, EarlyView.
In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang, Haimei Wen, Ying Chen, Jingya Ning, Di Hu, Yujiao Dong, Chenyu Yao, Bo Yuan, Shuanying Yang   +8 more
wiley   +1 more source